After a long lull on the targeted therapies front – outside of EGFR T790M in lung cancer – this year’s ASCO has plenty to be cheerful about with new data across multiple tumour types. We can’t cover them all here, but more will be discussed in the Daily Live Blogs starting on Saturday.
Which drugs are going to be in roaring back after a quiet period? Which ones will be having a more muted meeting?
For those of you who are working in the targeting therapy world, take heart, there is a future beyond cancer immunotherapy; it is not the universal panacea and will likely not cure every cancer, at least for now.
There’s still a market opportunity for targeted therapies in cancer, and as we mentioned in yesterday’s ASCO Preview, there is also potential for the combination of targeted therapies with immunotherapies, so long as the combined toxicity is manageable and doesn’t outweigh the benefits.
In this post we’re looking at a selection of targeted therapies in a variety of tumour types. There’s a lot to choose from at ASCO this year.
Here’s a few we think are worth highlighting upfront.
Subscribers can log-in to learn more or you can become a member of the burgeoning BSB Community who appreciate the value of education, information and, even occasionally, infotainment…